Professional paper
https://doi.org/10.20471/acc.2022.61.s3.12
Systemic Triple Therapy in Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Tomislav Omrčen
orcid.org/0000-0002-7656-7877
; Department of Oncology and Radiotherapy, University Hospital Split, Split, Croatia; School of Medicine, University of Split, Split, Croatia
Abstract
For many years, androgen deprivation therapy (ADT) as monotherapy has been the
gold standard for metastatic hormone-sensitive prostate cancer (mHSPC) treatment. Several studies
have been published within the last decade demonstrating a significant survival advantage resulting
from combining the treatment with standard ADT plus docetaxel or androgen receptor targeted
therapy (ARTA) compared to ADT monotherapy. Recently published data of the PEACE-1 and
ARASENS trials suggest that in the future, triple therapy might be a treatment option for patients
with mHSPC.
Keywords
Hormone-sensitive Prostate Cancer; Systemic Therapy; Novel Hormonal Therapy; Taxanes; Triple Therapy
Hrčak ID:
286376
URI
Publication date:
1.10.2022.
Visits: 1.239 *